Human Microbiome Market Scope And Analysis

Report Code : TIPBT00002233
Category : Life Sciences

Status : Published
No. of Pages : 172

Buy Now

Human Microbiome Market Scope, Growth, Size and Share by 2028

Buy Now

Human Microbiome Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 1.07 Billion
Market Size by 2031	US$ 4.84 Billion
Global CAGR (2023 - 2031)	20.8%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Type Product Software and Services By Application Therapeutics Diagnostics Research By Disease Type Obesity Diabetes Autoimmune Disorder Cancer GIT Disorders
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	MaaT Pharma Ferring Holdings SA Finch Therapeutics Group Inc AOBiome Therapeutics Inc Seres Therapeutics Inc Merck Co Inc Yakult Honsha Co Ltd Rebiotix Inc IFF Nutrition Biosciences Synthetic Biologics Inc

Human Microbiome Market News and Recent Developments

The human microbiome market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:

MaaT Pharma announced the launch of a retrospective multicenter trial called CHRONOS in Europe. Its objective is to provide the Company efficacy data for 3rd-line therapies for patients not receiving MaaT013 or any microbiome intervention. This study was not requested by regulatory authorities and does not impact cash projections, as funding has already been secured. (Source: MaaT Pharma, Company Website, March 2024).
Seres Therapeutics, Inc. has received U.S. Food and Drug Administration (FDA) clearance for SER-155 under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia, and graft-versus-host disease (GvHD) in immunocompromised patients. (Source: Seres Therapeutics, Inc, Company Website, June 2021)

Human Microbiome Market Report Coverage and Deliverables

The "Human Microbiome Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

Human microbiome market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Human microbiome market trends, as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST and SWOT analysis
Human microbiome market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the human microbiome market
Detailed company profiles